O-1 Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma
Titel:
O-1 Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma
Auteur:
Ducreux, M. Abou-Alfa, G. Ren, Z. Edeline, J. Li, Z. Assenat, E. Rimassa, L. Blanc, J. Ross, P. Fang, W. Hu, S. Zhang, T. Tran, A. Pan, H. Yen, C. Wu, J. Li, V. Chica-Duque, S. Merle, P. Cheng, A.